My Watchlist

Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.

Recs

2

Should VIVUS Look for a Buyer?

By | More Articles
November 16, 2012 | Comments (1)

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

VIVUS (Nasdaq: VVUS  ) , the pharma company that just started selling its new obesity drug Qsymia, may not be angling for a buyout; but it sounds like one of its shareholders, QVT Financial, thinks this is the best possible strategy.

In the following video, health-care analysts Max Macaluso and David Williamson discuss this news, and whether a buyout makes sense for the under-fire drugmaker.

The ravages of America's obesity epidemic are a challenge of epic proportions. However, a group of drug companies are looking to change everything. Newly-approved drugs, including one developed by VIVUS, could help to reverse this deadly course while reaping massive profits for investors in the process. The profit opportunity is immense, but plenty of risks still exist, so make sure that you understand the full story behind VIVUS in the Fool's brand new premium research service. It's such an important story that we have our top health-care writer on the job, so make sure to secure a copy today by clicking here now.

Jeff Fischer and team have demystified options. And they can rack up income like $1,030... $2,626... and $3,228 on a schedule you can set your watch by!
That's why we're glad to announce every single one of their closely guarded strategies is available to YOU during May and June – 100% FREE, no strings attached! Just enter your email address in the box below...

David Williamson has no positions in the stocks mentioned above. Max Macaluso, Ph.D. has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Read/Post Comments (1) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On November 19, 2012, at 8:51 AM, PRODOD wrote:

    The idea of a buyout of VVUS is laughable: $41K in sales & a drug that cannot be sold in europe is not likely to command a takout premium. The only thing eyeing VVUS are buzzards -- not big pharma!

Add your comment.

Compare Brokers

Fool Disclosure

DocumentId: 2117805, ~/Articles/ArticleHandler.aspx, 5/20/2013 3:14:23 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 15,350.20 -4.20 -0.03%
S&P 500 1,667.72 0.25 0.01%
NASD 3,498.62 -0.35 -0.01%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

5/20/2013 2:57 PM
VVUS $12.92 Up +0.62 +5.04%
VIVUS, Inc. CAPS Rating: **
OREX $6.02 Down -0.02 -0.33%
Orexigen Therapeut… CAPS Rating: **
ARNA $7.95 Down -0.03 -0.36%
Arena Pharmaceutic… CAPS Rating: **

Advertisement